Login to Your Account



ASN Roundup


Tuesday, November 15, 2011
• Concert Pharmaceuticals Inc., of Lexington, Mass., reported Phase I data showing that a controlled-release version of CTP-499, an analogue of 1-([S]-5-hydroxyhexyl)-3,7-dimethylxanthine (HDX), was well tolerated at single doses up to an including 1,800 mg.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription